Skip to content

Aurinia Pharmaceuticals AUPH Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$21.95M+157%
Alumis Inc. logo
Alumis Inc.ALMS
-$93.71M+5.4%
Alkermes logo
AlkermesALKS
-$67.29M-393%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$98.27M+32.3%
Arrowhead Research logo
Arrowhead ResearchARWR
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Aurinia Pharmaceuticals (AUPH) reported comprehensive income (loss), net of tax, attributable to parent of $34.07M in Q1 2026.
How has Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 47.1% year-over-year, from $23.17M to $34.07M.
What is the long-term trend for Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 12.2% compound annual growth rate (CAGR), from -$181.01M to $287.25M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric reflects the total change in equity from non-owner sources, including net income and other items that bypass the traditional income statement, such as unrealized gains or losses on investments and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance and changes in net worth beyond standard operating results. Investors use this to assess the broader economic impact on the company's financial position that is not captured by net income alone.